Androgen receptor expression and its relationship with clinicopathological parameters in an Iranian population with invasive breast carcinoma


1 Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Androgen receptor (AR) status and its association with prognosis in Iranian breast cancer population are uncertain. We examined AR expression and its relationship with clinicopathological parameters among Iranian patients with invasive breast carcinoma.
Materials and Methods: This study was performed on formalin fixed and paraffin embedded tissue specimens with a diagnosis of invasive breast carcinoma archived at two University Hospitals in Isfahan city, Iran. Antibodies were used for evaluation of AR, human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR). Other data were gathered from patients' documents.
Results: A total of 70 cases were evaluated including 55 (78.6%) ductal, 9 (12.9%) lobular, 2 (2.9%) medullary, and 4 (5.7%) mucinous carcinomas. Overall, 48.6%, 42.9%, 64.3%, and 57.1% of the samples were positive for ER, PR, AR, and HER2, respectively. Thirty three (47.1%) cases were ER PR and 17.1% were triple negative. AR + cases were younger and more frequently positive for ER and showed less frequently tumor size of > 2 cm. Although tumor grade and stage were relatively higher among AR cases compared to AR + ones, the difference between the two groups was not statistically significant.
Conclusions: AR expression was found to be frequently present in breast carcinoma in the studied population. Since half of the ER negative and half of the triple negative tumors were found to be AR positive, AR positive cases may benefit from alternative endocrine therapeutic strategies other than the conventional endocrine-targeted medications.


1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.  Back to cited text no. 1
2. Sadjadi A, Nouraie M, Ghorbani A, Alimohammadian M, Malekzadeh R. Epidemiology of breast cancer in the Islamic Republic of Iran: First results from a population-based cancer registry. East Mediterr Health J 2009;15:1426-31.  Back to cited text no. 2
3. Bernard-Marty C, Lebrun F, Awada A, Piccart MJ. Monoclonal antibody-based targeted therapy in breast cancer: Current status and future directions. Drugs 2006;66:1577-91.  Back to cited text no. 3
4. Perez EA. Breast cancer management: Opportunities and barriers to an individualized approach. Oncologist 2011;16 Suppl 1:20-2.  Back to cited text no. 4
5. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 1998;3:95-103.  Back to cited text no. 5
6. Garay JP, Park BH. Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res 2012;2:434-45.  Back to cited text no. 6
7. Wang SY, Shamliyan T, Virnig BA, Kane R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis. Breast Cancer Res Treat 2011;127:1-14.  Back to cited text no. 7
8. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008;14:8019-26.  Back to cited text no. 8
9. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.  Back to cited text no. 9
10. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-8.  Back to cited text no. 10
11. Lippman M, Bolan G, Huff K. The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976;36:4610-8.  Back to cited text no. 11
12. Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004;112:312-8.  Back to cited text no. 12
13. Zumoff B, Levin J, Rosenfeld RS, Markham M, Strain GW, Fukushima DK. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res 1981;41:3360-3.  Back to cited text no. 13
14. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer: Current status and future directions. Ann Oncol 2009;20:1913-27.  Back to cited text no. 14
15. McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 2013;133:66-76.  Back to cited text no. 15
16. Hudis CA, Gianni L. Triple-negative breast cancer: An unmet medical need. Oncologist 2011;16 Suppl 1:1-11.  Back to cited text no. 16
17. Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC, et al. Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 2008;8:149.  Back to cited text no. 17
18. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003;120:725-31.  Back to cited text no. 18
19. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009;69:6131-40.  Back to cited text no. 19
20. Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 2011;17:1867-74.  Back to cited text no. 20